/
Neurology
Huntington's Disease
8
Pipeline Programs↗
20
Active Trials↗
21
Companies Involved↗
Huntington's Disease is an early-stage landscape with 8 programs across 21 companies. The most active players are Neurocrine Biosciences, Roche. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 21
Phase 31
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 75% of 8 pipeline programs.
Analysis
Trial Status
103
clinical trials
Completed61 · 59%
Terminated15 · 15%
Recruiting9 · 9%
Active, not recruiting8 · 8%
Unknown status7 · 7%
Enrolling by invitation2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
103 trials
Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT04478734·24 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)